Related Experiment Video
Updated: Jan 7, 2026

Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
Published on: March 24, 2013
Rethinking First-Line Therapy and Beyond: HER2-Positive and Hormone Receptor-Positive/HER2-Negative Metastatic Breast
Wolfgang Janni1, Rebecca A Dent2, Peter Schmid3
1Department of Obstetrics and Gynecology, Ulm University Hospital, Universitätsfrauenklinik Ulm, Ulm, Germany.
Abstract:
Recent advances in metastatic breast cancer have fundamentally altered treatment paradigms, offering new hope for patients while challenging clinicians to adapt their approaches to patient care. This article summarizes expert perspectives from a symposium presented at the 2025 European Society for Medical Oncology Congress, examining how emerging data in HER2-positive metastatic breast cancer and hormone receptor-positive metastatic breast cancer are reshaping clinical decision-making, patient selection strategies, and personalized approaches. Key developments include the evolution of antibody-drug conjugates in HER2-positive disease, biomarker-guided therapy selection using ESR1 mutation monitoring, and novel treatment strategies for patients with hormone-refractory disease. These advances necessitate understanding of patient selection criteria, toxicity management, and sequential therapy planning to optimize outcomes in this expanding therapeutic landscape.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...